# Animal Models of Narcolepsy: From Orexin Deficiency to Immune Mechanisms and Regenerative Therapies

**Authors:** Oscar Arias-Carrión, Emmanuel Ortega-Robles

PMC · DOI: 10.3390/cimb47110874 · 2025-10-22

## TL;DR

This review explores how animal models have advanced understanding of narcolepsy, from orexin deficiency to immune and regenerative therapies, and outlines future directions for better models and cures.

## Contribution

The paper proposes a unified roadmap integrating immune, cellular, and computational approaches to improve narcolepsy models and therapies.

## Key findings

- Early models showed orexin loss causes narcolepsy type 1, but fail to fully replicate human symptoms.
- Immune-driven and regenerative models offer new insights and therapeutic strategies for narcolepsy.
- Combining multi-omics and novel models could lead to long-term cures beyond symptom management.

## Abstract

Animal models have been pivotal in uncovering the orexin (hypocretin) system as the fulcrum of sleep–wake regulation and in shaping therapeutic discovery for narcolepsy. Early canine and murine models established that orexin loss underlies narcolepsy type 1, while conditional and receptor-specific manipulations refined mechanistic insight. However, current paradigms capture only fragments of the human phenotype, often exaggerating cataplexy and under-representing narcolepsy type 2. Here, we follow the evolution of narcolepsy modelling from classical knockout and receptor-deficient systems to immune-driven and cell-replacement models, identifying critical translational gaps and proposing strategies to bridge them. We highlight how immune-competent mouse lines, astrocyte-to-neuron reprogramming, and patient-derived hypothalamic organoids bridge pathogenic insight with therapeutic innovation. Integrating these advances with small-molecule OX2R agonists, gene therapy, and multi-omics-based patient stratification defines a roadmap for moving beyond symptomatic control. This review seeks to unify immune, cellular, and computational perspectives to guide the next generation of animal models toward the prevention, repair, and long-term cure of narcolepsy.

## Linked entities

- **Proteins:** hcrt (hypocretin (orexin) neuropeptide precursor), HCRTR2 (hypocretin receptor 2)
- **Diseases:** narcolepsy (MONDO:0021107), narcolepsy type 1 (MONDO:0016158), narcolepsy type 2 (MONDO:0019371)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** HCRT (hypocretin neuropeptide precursor) [NCBI Gene 3060] {aka NRCLP1, OX, PPOX}, HCRTR2 (hypocretin receptor 2) [NCBI Gene 3062] {aka ORXR2, OX2R, OXR2}
- **Diseases:** Orexin Deficiency (MESH:D007153), narcolepsy type 1 (MESH:C563534), cataplexy (MESH:D002385), Narcolepsy (MESH:D009290)
- **Species:** Homo sapiens (human, species) [taxon 9606], Canis lupus familiaris (dog, subspecies) [taxon 9615], Mus musculus (house mouse, species) [taxon 10090]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12650821/full.md

---
Source: https://tomesphere.com/paper/PMC12650821